IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria
|
Jun 2023
|
Blood
|
aplastic anemia
|
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
|
Aug 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure
|
Jun 2016
|
Blood
|
myelodysplastic syndromes (MDS)
|
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)
|
Jul 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
|
Dec 2015
|
Blood
|
myelodysplastic syndromes (MDS)
|
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes
|
Sep 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
|
Jul 2020
|
Blood
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
|
Jan 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
|
Jun 2023
|
Blood
|
aplastic anemia
|
Recent developments in myelodysplastic syndromes
|
Sep 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|